Myasthenia Gravis and Its ComorbiditiesBernardo Cacho Diaz1*, Paola Flores-Gavilán2, Guillermo García-Ramos3 and Nydia A. Lorenzana-Mendoza2
- *Corresponding Author:
- Bernardo Cacho Diaz
Neurology coordinator at the Instituto Nacional de Cancerología (National Cancer Institute)
Mexico City. Av. San Fernando 22. Col. Sección XVI. ZC 14,080. Mexico City
Tel: (525) 2127-1049
E-mail: [email protected]
Received date: September 16, 2015; Accepted date: September 22, 2015; Published date: September 29, 2015
Citation: Bernardo Cacho Diaz, Paola Flores-Gavilán, Guillermo García-Ramos and Nydia A. Lorenzana-Mendoza (2015) Myasthenia Gravis and Its Comorbidities. J Neurol Neurophysiol 6:317. doi:10.4172/2155-9562.1000317
Copyright: © 2015 Bernardo CD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Myasthenia gravis (MG) is an unpredicted neurologic disorder that may cause death; previous reports have failed to find a prognostic marker for the disease. Aim: To determine the impact of comorbidities in patients with Myasthenia gravis. Material and Methods: From January of 2002 to February of 2008 a database was created for patients with Myasthenia gravis (MG). The following variables were studied: age at onset of MG, gender, diabetes mellitus, dyslipidemia, arterial hypertension, dysthyroidism, autoimmune disease, thymectomy procedure and histopathologic result, myasthenic crisis, emergency room visits due to weakness, use and maximum dose of pyridostigmine, prednisone and azathioprine. Results: In a total of 253 patients, we found comorbidities in 73%. The most frequent associated disorders were dyslipidemia, thyroid disease, diabetes, hypertension and other autoimmune conditions. Patients with MG and thymoma, diabetes, dyslipidemia, dysthyroidism and/or hypertension had higher rates of ER visits, myasthenic crises, and required higher doses of drugs. Conclusions: This study demonstrates that comorbidities are frequent in patients with MG (73%) and that they might worsen the prognosis of MG.